IBDEI09L ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4430,1,3,0)
 ;;=3^277.30
 ;;^UTILITY(U,$J,358.3,4430,1,4,0)
 ;;=4^AMYLOIDOSIS NOS
 ;;^UTILITY(U,$J,358.3,4430,2)
 ;;=^334185
 ;;^UTILITY(U,$J,358.3,4431,0)
 ;;=277.31^^37^430^3
 ;;^UTILITY(U,$J,358.3,4431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4431,1,3,0)
 ;;=3^277.31
 ;;^UTILITY(U,$J,358.3,4431,1,4,0)
 ;;=4^FAM MEDITERRANEAN FEVER
 ;;^UTILITY(U,$J,358.3,4431,2)
 ;;=^189367
 ;;^UTILITY(U,$J,358.3,4432,0)
 ;;=277.39^^37^430^2
 ;;^UTILITY(U,$J,358.3,4432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4432,1,3,0)
 ;;=3^277.39
 ;;^UTILITY(U,$J,358.3,4432,1,4,0)
 ;;=4^AMYLOIDOSIS,OTHER
 ;;^UTILITY(U,$J,358.3,4432,2)
 ;;=^334034
 ;;^UTILITY(U,$J,358.3,4433,0)
 ;;=446.21^^37^430^4
 ;;^UTILITY(U,$J,358.3,4433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4433,1,3,0)
 ;;=3^446.21
 ;;^UTILITY(U,$J,358.3,4433,1,4,0)
 ;;=4^GOODPASTURE'S SYNDROME
 ;;^UTILITY(U,$J,358.3,4433,2)
 ;;=^52601^583.81
 ;;^UTILITY(U,$J,358.3,4434,0)
 ;;=580.0^^37^430^8
 ;;^UTILITY(U,$J,358.3,4434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4434,1,3,0)
 ;;=3^580.0
 ;;^UTILITY(U,$J,358.3,4434,1,4,0)
 ;;=4^NEPHRITIS,AC PROLIFERATIVE
 ;;^UTILITY(U,$J,358.3,4434,2)
 ;;=^270338
 ;;^UTILITY(U,$J,358.3,4435,0)
 ;;=580.4^^37^430^9
 ;;^UTILITY(U,$J,358.3,4435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4435,1,3,0)
 ;;=3^580.4
 ;;^UTILITY(U,$J,358.3,4435,1,4,0)
 ;;=4^NEPHRITIS,AC RAPIDLY PROGR
 ;;^UTILITY(U,$J,358.3,4435,2)
 ;;=^270339
 ;;^UTILITY(U,$J,358.3,4436,0)
 ;;=580.9^^37^430^7
 ;;^UTILITY(U,$J,358.3,4436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4436,1,3,0)
 ;;=3^580.9
 ;;^UTILITY(U,$J,358.3,4436,1,4,0)
 ;;=4^NEPHRITIS,AC NOS
 ;;^UTILITY(U,$J,358.3,4436,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,4437,0)
 ;;=582.0^^37^430^14
 ;;^UTILITY(U,$J,358.3,4437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4437,1,3,0)
 ;;=3^582.0
 ;;^UTILITY(U,$J,358.3,4437,1,4,0)
 ;;=4^NEPHRITIS,CHR PROLIFERATIVE
 ;;^UTILITY(U,$J,358.3,4437,2)
 ;;=^270347
 ;;^UTILITY(U,$J,358.3,4438,0)
 ;;=582.1^^37^430^12
 ;;^UTILITY(U,$J,358.3,4438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4438,1,3,0)
 ;;=3^582.1
 ;;^UTILITY(U,$J,358.3,4438,1,4,0)
 ;;=4^NEPHRITIS,CHR MEMBRANOUS
 ;;^UTILITY(U,$J,358.3,4438,2)
 ;;=^24388
 ;;^UTILITY(U,$J,358.3,4439,0)
 ;;=582.2^^37^430^11
 ;;^UTILITY(U,$J,358.3,4439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4439,1,3,0)
 ;;=3^582.2
 ;;^UTILITY(U,$J,358.3,4439,1,4,0)
 ;;=4^NEPHRITIS,CHR MEMBRANOPROLIF
 ;;^UTILITY(U,$J,358.3,4439,2)
 ;;=^24386
 ;;^UTILITY(U,$J,358.3,4440,0)
 ;;=582.4^^37^430^15
 ;;^UTILITY(U,$J,358.3,4440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4440,1,3,0)
 ;;=3^582.4
 ;;^UTILITY(U,$J,358.3,4440,1,4,0)
 ;;=4^NEPHRITIS,CHR RAPID PROGR
 ;;^UTILITY(U,$J,358.3,4440,2)
 ;;=^270348
 ;;^UTILITY(U,$J,358.3,4441,0)
 ;;=582.81^^37^430^10
 ;;^UTILITY(U,$J,358.3,4441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4441,1,3,0)
 ;;=3^582.81
 ;;^UTILITY(U,$J,358.3,4441,1,4,0)
 ;;=4^NEPHRITIS,CHR IN OTH DIS
 ;;^UTILITY(U,$J,358.3,4441,2)
 ;;=^270350
 ;;^UTILITY(U,$J,358.3,4442,0)
 ;;=582.9^^37^430^13
 ;;^UTILITY(U,$J,358.3,4442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4442,1,3,0)
 ;;=3^582.9
 ;;^UTILITY(U,$J,358.3,4442,1,4,0)
 ;;=4^NEPHRITIS,CHR NOS
 ;;^UTILITY(U,$J,358.3,4442,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,4443,0)
 ;;=583.81^^37^430^5
 ;;^UTILITY(U,$J,358.3,4443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4443,1,3,0)
 ;;=3^583.81
 ;;^UTILITY(U,$J,358.3,4443,1,4,0)
 ;;=4^NEPHRITIS IN OTH DIS
 ;;^UTILITY(U,$J,358.3,4443,2)
 ;;=^82243
 ;;^UTILITY(U,$J,358.3,4444,0)
 ;;=583.81^^37^430^16
 ;;^UTILITY(U,$J,358.3,4444,1,0)
 ;;=^358.31IA^4^2
